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Abstract: A recombinant subunit vaccine (Shingrix®) was recently licensed for use against herpes
zoster. This vaccine is based on glycoprotein E (gE) of varicella zoster virus (VZV), the most
abundantly expressed protein of VZV, harboring sites for N- and O-linked glycosylation. The subunit
vaccine elicits stronger virus-specific CD4+ T cell response as well as antibody B cell response to gE,
compared to the currently used live attenuated vaccine (Zostavax®). This situation is at variance
with the current notion since a live vaccine, causing an active virus infection, should be far more
efficient than a subunit vaccine based on only one single viral glycoprotein. We previously found
gE to be heavily glycosylated, not least by numerous clustered O-linked glycans, when it was
produced in human fibroblasts. However, in contrast to Zostavax®, which is produced in fibroblasts,
the recombinant gE of Shingrix® is expressed in Chinese hamster ovary (CHO) cells. Hence, the glycan
occupancy and glycan structures of gE may differ considerably between the two vaccine types. Here,
we aimed at (i) defining the glycan structures and positions of recombinant gE and (ii) identifying
possible features of the recombinant gE O-glycosylation pattern contributing to the vaccine efficacy
of Shingrix®. Firstly, recombinant gE produced in CHO cells (“Shingrix situation”) is more scarcely
decorated by O-linked glycans than gE from human fibroblasts (“Zostavax situation”), with respect
to glycan site occupancy. Secondly, screening of immunodominant B cell epitopes of gE, using a
synthetic peptide library against serum samples from VZV-seropositive individuals, revealed that the
O-linked glycan signature promoted binding of IgG antibodies via a decreased number of interfering
O-linked glycans, but also via specific O-linked glycans enhancing antibody binding. These findings
may, in part, explain the higher protective efficacy of Shingrix®, and can also be of relevance for
development of subunit vaccines to other enveloped viruses.
Keywords: antibody binding; B cell epitope; glycoprotein E; glycosylation; vaccine; varicella
zoster virus
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1. Introduction
Herpes zoster (HZ) or shingles is a result of reactivation of latent varicella zoster virus (VZV)
from dorsal root or cranial nerve ganglia. The seroprevalence of VZV IgG exceeds 90% in most adult
populations and, thereby, a large number of individuals are at risk of developing HZ. A live attenuated
vaccine (Zostavax®, Merck) is licensed for use in individuals≥50 years of age. However, the protective
efficacy against HZ is rather modest, at 51.3%, and declines with increasing age, i.e., 66.5% between
50 and 59 years, and only 37.6% above the age of 70 [1,2]. Recently, a recombinant subunit vaccine
(HZ/su, Shingrix®, Glaxo Smith-Kline Biologicals) was developed and licensed for use against HZ.
This vaccine is based on the single glycoprotein E (gE) and the adjuvant AS01B. This envelope protein
is highly expressed on VZV viral particles and on infected cells, and functions as a Fc receptor for
human immunoglobulin G (IgG) [3]. The efficacy of the subunit vaccine is as high as 97.2%, and with
no sign of declining potency with increasing patient age [4,5]. Earlier clinical trials have shown that
one dose of the recombinant subunit vaccine elicits stronger gE and VZV-specific CD4+ T cell and
antibody B cell responses than two doses of the live attenuated vaccine [6–8]. When both vaccines
were administered simultaneously, there was no increase either in cellular or humoral responses to gE,
as compared to giving the recombinant vaccine alone [6]. Recent comparative studies have highlighted
that the superior efficacy of the recombinant subunit vaccine can be explained by its ability to generate
a higher T cell memory response compared to the live vaccine [9,10]. Still, the question remains: How
can a vaccine based only on one single glycoprotein outcompete a live virus (although attenuated)
vaccine that actually results in an active virus infection?
Human herpesviruses belong to the Herpesviridae family of large enveloped DNA viruses,
where the genomes have the capacity to encode between ~70 and ~230 proteins, including various
glycoproteins that protrude from the viral surface [11]. Many of these proteins are engaged in
subversion of the host immune system, a critical prerequisite for human herpesviruses to establish a
lifelong latent infection in their host, which is a hallmark for these viruses [12]. A prevailing notion
in vaccinology is that live attenuated VZV virus mimics an authentic infection, thereby mounting
a complete B and T cell response with capacity to address all of the almost 100 proteins introduced
by VZV [13,14]. This includes all components of the viral particle, especially all glycoproteins that
are present in the viral particle, but also exposed on the surface of infected cells. Yet, the subunit
vaccine, which is based solely on one single viral glycoprotein designated gE, can provide a B and T
cell response against this protein that even surpasses that of the live attenuated vaccine [1,6,7].
The high potency of gE as a vaccine immunogen, irrespective if it is administered as a subunit
or live HZ vaccine, probably depends on several factors, not least its predominance at the surface of
VZV viral particles. However, another important aspect of gE is its structural organization; it harbors
two consensus N-glycosylation sites (Asn–X–Ser/Thr) but also contains a so-called mucin-like domain
(MLD), a peptide stretch that is rich in Pro, Ser, and Thr residues, and constitutes a target for mucin-type
O-linked glycosylations [15,16]. O-linked glycosylation of viral MLDs is initiated by addition of
N-acetylgalactosamine (GalNAc) via an O-glycosidic linkage to single or combinations of multiple
Ser and Thr residues of the MLD [17,18]. Owing to viral interference with O-glycan elongation,
much of these carbohydrate components of viral MLDs are composed of shorter glycans, including
O-linked GalNAc monosaccharides (Tn antigen) and GalGalNAc disaccharides (T antigen) [16,19,20].
Recently, we established that such truncated O-linked glycans, in combination with the proximate
peptide sequence at the glycosylation site, forms a novel variant of viral B cell epitope to which
prominent antibody responses are raised in the infected patient [21–23]. Importantly, it was shown
that a single GalNAc unit and each specific amino acid of the glycopeptide stretch contributed equally
well to the B cell epitope specificity and avidity towards the cognate antibody [22,23]. Although
the exact contribution of the MLD to the VZV gE subunit vaccine is not clarified, it is interesting to
note that another successful subunit viral vaccine, i.e., the hepatitis B virus (HBV) subunit vaccine,
is also based on a single viral envelope glycoprotein containing multiple MLD stretches [24,25].
Moreover, we recently defined the attachment sites of O-linked glycans within VZV gE obtained from
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infected fibroblasts and from a clinical sample, including several sites within the MLD domain of the
protein [16].
The contribution of viral MLDs to glycopeptide B cell epitope is still incompletely understood.
This is at least partly due to the complexity of both initiation and elongation of O-linked glycosylation,
which confers a natural variability in the expressed structures. Thus, firstly, O-linked glycosylation
may or may not occur at a specific amino acid residue and, secondly, different glycan structures may
be found at that same position, depending on expression levels of glycosyltransferases which vary
between cell and tissue types, but also between different species [26–28]. Hence, the choice of the
cell system used for vaccine production is a critical parameter to ensure production of an optimal
immunogen with respect to presentation of adequate T and B cell glycopeptide epitopes.
We have previously defined, in detail, the GalNAc occupancy of the potential O-glycosylation
sites of human fibroblast-produced gE, the same cell type that is used for production of the live
attenuated HZ vaccine [16]. In the present study, we defined the site-specific glycan structures of
the recombinant gE expressed in Chinese hamster ovary (CHO-K1) cells, the same cell line used to
produce the subunit vaccine, and show (i) that the glycans are important for antibody recognition
and (ii) that there are distinct differences in the O-glycan occupancy compared with gE derived from
human fibroblasts. In addition, we aimed at defining the immunodominant B cell epitopes of the
recombinant gE using synthetic peptides and glycopeptides by screening of serum samples from
VZV-seropositive and VZV-seronegative individuals.
2. Results
2.1. Glycosylation of the Recombinant gE Produced in CHO-K1 Cells
The live HZ vaccine and the subunit HZ vaccine are derived from different types of producer
cell lines, which is likely to result in important differences in the glycoprotein glycosylation status
between the two vaccine constructs. VZV gE, produced in human diploid fibroblasts as part of whole
virus infection and used for Zostavax® live virus vaccine production, has been characterized in detail
with respect to the O-linked glycosylation of this protein [16]. Here, we first aimed at structurally
characterizing the O-linked glycans and glycosylation positions of a VZV gE construct (gE HZ/su
prototype (gEHP)) derived from CHO-K1 cells, the cell line used for production of the Shingrix®
subunit vaccine (HZ/su), to reveal possible differences in O-linked glycosylation of gE between the
two vaccine variants. To distinguish between the two variants, gE derived from VZV infected human
diploid fibroblasts is hereafter referred to gE live (gEL).
In order to define the site-specific glycan structures of the gEHP, the isolated protein was subjected
to liquid chromatography tandem mass spectrometry (LC–MS/MS) analysis. At first, gEHP was
subjected to on-membrane trypsin cleavage. This enabled only 34% coverage of the total protein
length when the tryptic peptides and glycopeptides were analyzed with LC–MS/MS. In order to
also study peptide stretches that may be suboptimal for tryptic cleavage sites in gEHP, an additional
on-membrane pronase treatment was included in order to generate additional peptide fragments
by increasing the number of potential cleavage sites. This resulted in an increased coverage, with
a total coverage of 62% when the two methods were combined (Figure S1). We used ETD-induced
fragmentation of the trypsin-digested glycopeptides to provide peptide backbone fragmentation into
the c- and z-ion series while keeping the glycans intact, thus pinpointing glycosylation sites (Table S1).
Also, HCD-induced glycosidic fragmentation of the glycans and simultaneous peptide fragmentation
into the b- and y-ion series was undertaken to identify additional O-glycopeptides, and to define the
structures of individual glycans (Figures 1 and S2). In total, we found eleven Ser and Thr residues
to be glycosylated, which were found in three clusters of gEHP, as shown in Figure 2 and Table S1.
The O-linked glycans were all composed of the core 1 HexHexNAc structure (Galβ3GalNAcα1-O-)
and were mainly disialylated with N-acetylneuraminic acid (NeuAc) both at the inner GalNAc and at
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the terminal Gal (Figures 1A,B and 2) in the O-glycan epitope cluster I (GC-I). Monosialylated variants
of the core 1 type dominated in the GC-II and GC-III clusters (Figures 1A,B and 2).Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 21 
 
Figure 1. LC–MS/MS spectra after pronase and trypsin treatment of gEHP. Shown are representative 
spectra covering amino acid 325-TRNPTPAVTPQPR-337. T329 and T333 were found to (A,B) carry 
monosialylated and disialylated core 1 O-linked glycans. Also, (C) NeuAc(Ac) variants and (D) 
NeuGc variants were identified. In total, trypsin and pronase treatment resulted in 62% coverage of 
the total protein.  N-acetylgalactosamine (GalNAc),  galactose (Gal),  N-acetylneuraminic 
acid (NeuAc), and  N-glycolylneuraminic acid (NeuGc). 
Figure 1. LC–MS/MS spectra after pronase and trypsin treatment of gEHP. Shown are representative
spectra covering amino acid 325-TRNPTPAVTPQPR-337. T329 and T333 were found to (A,B) carry
monosialylated and disialylated core 1 O-linked glycans. Also, (C) NeuAc(Ac) variants and (D) NeuGc
variants were identified. In total, trypsin and pronase treatment resulted in 62% coverage of the total
protein.
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Also, an additional O-acetyl group of NeuAc (NeuAc(Ac)) was identified both in the GC-I and in
the GC-II cluster (Figures 1C and 2 and Table S1). It was signified by the presence of diagnostic
oxonium ions corresponding to NeuAc(Ac) and NeuAc(Ac)–H2O at m/z 334.11 and m/z 316.10
(Figure 1C), whereas the corresponding NeuAc oxonium ions only possess the m/z 292.10 and 274.09
ions (Figure 1A,B). Moreover, the nonhuman sialic acid N-glycolylneuraminic acid (NeuGc) was also
detected in the GC-I and the GC-II cluster (Figures 1D and 2 and Table S1). The NeuGc-specific
oxonium ion m/z 308.10 and 290.09 were here used for the diagnostic purposes. When the m/z
274.09, m/z 16.10, and m/z 290.09 ions were screened for in extracted ion chromatograms, it was
evident that the relative abundance of the NeuAc(Ac)- and NeuGc-containing glycoforms were
approximately at the 1%–2% level compared to that of NeuAc. There were observable differences
in attachment site occupancy found for different peptides of the GC-I and GC-III clusters (Figures 2
and S3). However, both non-glycosylated and glycosylated peptides were only found simultaneously
for two of the trypsin-digested regions (marked None regarding modification in Table S1). For the
73-KAYDHNSPYIWPR-85 region, 3%–16% of the peptides were found to be glycosylated, assuming
that the glycopeptides and peptides ionize equally well (Figure S3A–D). In comparison, for the
524-EITPVNPGTSPLLR-537 peptides, the degree of glycosylation was 54% (Figure S3E,F).
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Figure 2. Schematic drawing of varicella zoster virus (VZV) gE, gEL, and gEHP with an outline
of the glycan compositions a d positions n the peptide sequence of gEHP as determined by mass
spectrometry in the present study. Three O-linked glycan epitope clusters (GC) of sialylated core 1
O-linked glycans and one complex type N-linked glycan were found. Two O-linked glycans were
situated within the linear B cell epitope (green) [29] while the largest cluster of O-linked glycans was
found in the mucin-like domain (MLD) (yellow) close to the transmembrane domain (purple). For gEHP,
neither the IDE domain (red) nor the gI-binding omain (blue) contained any gl ca s, while O-linked
glycans w re fou d in the corresponding domains of gEL [30].
There are two potential sites for N-linked glycosylation within gEHP protein sequence (Asn-266
and Asn-437). The peptide coverage enabled analysis only of Asn-437, which was indeed found to
carry an N-linked glycan (Figures 2 and S4). The N-linked glycan was of the complex type with
2–3 antennae each carrying an N-acetylglucosamine (GlcNAc) followed by a galactose (Gal) residue,
and up to two NeuAc residues on the triantenna y struct s (Figure S4). The inner GlcNA residue
attached to the asparagine Asn-437 also ca ried an additio al fucose (Fuc) r sidue. No NeuGc- or
NeuAc(Ac)-containing glycoforms could be detected for the N-glycopeptides.
2.2. Removal of Glycans Negatively Impact Recognition of gEHP by Polyclonal Human Sera
The full length gEHP reac strongly with polyclonal sera isolated from individuals with
antibodies against VZV, as previously observed [31]. In or er to assess the impact of the glycan
structures on the serological response, we also trimmed and enzymatically removed the glycans on
gEHP prior to ELISA. The different enzymatic treatments conferred distinct size shifts as determined by
gel electrophoresis, indicating complete removal of glycans (Figure 3A). There was reduced reactivity
towards human polyclonal sera from VZV-positive individuals with high or intermediated antibody
titers (high titer n = 5, intermediate titer n = 5) when the deglycosylated gEHP was analyzed by
ELISA (Figure 3B). Removal of N-linked glycans by PNGaseF treatment and O-linked glycans by
O-glycosidase treatment independently reduced the reactivity by approximately 8% each, compared to
the mock-treated control, whereas removal of only the sialic acids did not confer any significant change
in serum reactivity. Removal of both N- and O-linked glycans did seem to have an additive effect
since there was a 17% reduction in reactivity in this sample compared to mock-treated. The untreated
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control sample, that was not subjected to any treatment but added at a higher concentration, behaved
as the mock-treated control sample (Figure 3B). The enzymatic hydrolysis for removal of O-linked
and N-linked glycans was almost complete as indicated by the distinct size shifts in the gel. Hence,
the majority of the reactivity of VZV-positive sera towards gEHP is restricted to peptide epitopes,
despite the 17% contribution of reactivity that was obviously positively modulated by glycans
(Figure 3B). However, this figure is the net effect of carbohydrate modulation of seroreactivity that
may also include peptide regions of gEHP for which glycosylation interferes with the seroreactivity of
particular epitopes of the protein.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 21 
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towards gEHP, either unmodified or deglycosylated, was assessed by ELISA using serum from VZV+
individuals (n = 10). Statistic calculations were done u ing one-way ANOVA with Tukey’s multiple
comparisons test (significance is indicated by ** p-values < 0.01 and **** p-values < 0.0001).
2.3. Single GalNAc Moieties Attached to Peptides Modulate Seroreactivity of Discrete gEHP Epitopes
To define single discrete epitopes and their relationship to modulation by O-linked glycans of
the gEHP, we generated a library of 16-, 18-, and 20-mer synthetic peptides covering 49% of the
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recombinant protein (Table S2) using previously published methods [22]. The peptides were produced
to cover the domains of gEHP that were previously shown to be immunodominant [29] and also
to cover the domains that carry glycan modifications as determined by LC–MS/MS (Figure 2 and
Table S2). The peptides were unglycosylated or carried single O-linked GalNAc modifications on serine,
threonine, or tyrosine residues. The peptides and glycopeptides were immobilized on a microarray
glass slide, and thereafter incubated with serum from verified VZV-positive (individual serum samples
n = 11 and pooled serum samples n = 2). The microarray slides were scanned, and the mean intensities
of fluorescence were determined, and average relative fluorescence unit (RFU) datasets were generated
from all serum samples (Figure S5). The number of different VZV-positive serum samples (IgG) that
reacted to the epitopes ranged between 0 and 10 (Table S2). We found that the antibody (glyco)peptide
epitopes of gEHP, reactive with the VZV-positive serum samples, were confined to four distinct clusters
along the protein amino acid sequence. The details are presented in Figure 2 and Table S2. When
all the peptides and glycopeptides were analyzed, three patterns emerged: (i) addition of a GalNAc
moiety conferred a reduction in average RFU-value, i.e., interference, (ii) addition of a GalNAc moiety
had no effect, and (iii) addition of a GalNAc moiety conferred an increase in average RFU-value,
i.e., enhancement. Interference of antibody binding was most prominently observed within the
region spanning W64-G140, including GC-I (Figure 2 and Table S2), the domain previously described
as the most antigenic [29]. We found a significant reduction in reactivity when a single GalNAc
residue was added either to a tyrosine or to a serine (Tyr-75, Ser-79, Tyr-81, and Tyr-88) of peptide
73-KAYDHNSPYIWPRNDYDG-90 (Figure 4A). Throughout the protein sequence, we could observe
peptide epitopes where addition of a GalNAc residue did not affect antibody binding, but this situation
was most evident in the region between GC-I and GC-II (Figure 2 and Table S2). Enhancement of
antibody binding was observed for peptide 460-GTTLKFVDTPESLSGLYV-477 when a GalNAc residue
was added to Ser-473 (Figure 4B).
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2.4. Detailed Characterization of Reactivity against Synthetic Peptides for Individual Sera
The individual serum RFU-values, against synthetic peptides either unglycosylated or carrying
single O-GalNAc modifications at the serine, threonine, or tyrosine residues, were further
characterized in detail. We examined the RFU-values for each peptide and each individual
serum sample (n = 11) in order to pinpoint the effect of glycosylation. When examining
the previously described immunodominant epitope spanning W64-G90, we found that peptide
64-WVNRGESSRKAYDHNSPY-81 was low- or non-reactive to all individual sera, both when
unglycosylated and when glycosylated at the potential sites for O-glycosylation (Figure 5A). On
the contrary, peptide 73-KAYDHNSPYIWPRNDYDG-90 was highly reactive in its unglycosylated
state, with all but one individual serum sample reacting to the peptide and displaying high
RFU-values, and when single GalNAc residues were added to the peptide, the reactivity was
abolished or severely reduced in all cases (Figure 5B). A closer inspection of the G111–G140
domain revealed a pattern where only a more limited stretch of the epitope showed reactivity.
The unglycosylated peptide 111-GERLMQPTQMSAQEDLGDDT-130 was non-reactive, and addition
of one GalNAc did not significantly alter the response (Figure 5C). The sequential peptide, i.e.,
121-SAQEDLGDDTGIHVIPTLNG-140, was evidently more reactive with three individual sera
displaying high RFU-values to the unglycosylated peptide. However, addition of a single GalNAc
residue to Ser-121 and Thr-137 appeared to enhance the RFU-values when the same serum samples
were added to this peptide stretch (Figure 5D). It thus appears that the B cell epitopes are narrow
peptide stretches that confer reactivity to individual sera, and that addition of a glycan epitope can
either decrease or increase the observed RFU-values in a uniform pattern, i.e., serum from the same
individual either show increased or decreased reactivity depending on the addition of a GalNAc moiety.
When analyzing peptides covering the stem region of the protein including the MLD,
which harbors several O-linked glycans, an even more heterogeneous pattern emerged. Peptide
460-GTTLKFVDTPESLSGLYV-477 showed no reactivity to any of the individual serum samples in
its unglycosylated state, whereas four individual sera showed enhanced, albeit modest, RFU-values
when the peptide carried a GalNAc residue at Ser-473 (Figure 6A). The stem region closer to the
transmembrane domain showed a more distinct effect of glycosylation on the serum response.
Peptides covering E505–A540 showed modest reactivity to only a few individual sera when they
were unglycosylated (Figure 6B–D). However, when a GalNAc residue was added to either Thr-512,
Thr-519, or Thr-520, there was a marked increase in RFU-values from serum samples 1, 2, and 7
(Figure 6B). Addition of a GalNAc residue to Thr-519, Thr-520, or Thr-526 increased RFU-values from
serum 4, 6, and 11 (Figure 6C) and addition of a GalNAc residue to Thr-526 or Ser-533 conferred
increased RFU-values from serum 1, 6, 7, 9, and 11 (Figure 6D). In the MLD domain of the stem
region, individual serum samples thus exhibited altered reactivity depending on where the GalNAc
residue was introduced within the peptide sequence, generating discrete immunological profiles for
the respective individual serum sample.
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Figure 5. A homogenous response towards synthetic peptides with single or multiple GalNAc
odifications was observed for peptides covering parts of the N-terminal region of gE. (A) Synthetic
peptide 64-WVNRGESSRKAYDHNSPY-81 unmodified or modified by GalNAc residues at either
Ser or Tyr, or a combination of both. (B) Synthetic peptide 73-KAYDHNSPYIWPRNDYDG-90
unmodified or modified by GalNAc residues at either Ser or Tyr. (C) Synthetic peptide
111-GERLMQPTQMSAQEDLGDDT-130 unmodified or modified by GalNAc residues at either Ser or
Thr, or a combination of both. (D) Synthetic peptide 121-SAQEDLGDDTGIHVIPTLNG-130 unmodified
or modified by GalNAc residues at either Ser or Thr. All peptides were incubated with serum samples
and the relative fluorescence unit (RFU)-values were determined. Grey: unglycosylated peptide. Blue:
GalNAc modification on a Ser residue. Yellow: GalNAc modification on a Tyr residue. Green: GalNAc
modification on a Thr residue. Blue and yellow: GalNAc modification on Ser and Tyr residues. Blue
and green: GalNAc modification on Ser and Thr residues. X-axis shows the individual serum samples
(n = 11) from VZV IgG-positive patients, plotted in the same order of individual sera in all graphs.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  11 of 21 
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modifications, was observed for peptides covering parts of gE close to the transmembrane domain,
including the MLD domain when individual serum samples were analyzed in detail. (A) Synthetic
peptide 460-GTTLKFVDTPESLSGLYV-477 unmodified or modified by GalNAc residues at either Ser
or Thr. (B) Synthetic peptide 505-EERGFPPTAGQPPATTKP-522 unmodified or modified by GalNAc
residues at Thr. (C) Synthetic peptide 514-GQPPATTKPKEITPVNPG-531 unmodified or modified by
GalNAc r sidues at Thr residues. (D) Synthetic peptide 523-KEITPV PGTSPLLRY-540 unmodified
or modified by GalNAc at either Ser or Thr residues. Grey: glycosylated peptide. Blue: GalNAc
modification on a Ser residue. Green: GalNAc modification on a Thr residue. X-axis shows the
individual serum samples (n = 11) from VZV IgG-positive patients, plotted in the same order of
individual sera in all graphs.
3. Discussion
Although direct head-to-head comparative clinical studies of immune protection against HZ
currently are lacking, the newly approved subunit vaccine Shingrix® (HZ/su), based on gE of VZV,
demonstrates efficacy data that seem to be superior to those of Zostavax®, the curre tly used live
atten ated vaccine [1,4,5]. At a first glance, this phenom non may appear paradoxical, as live vaccines
are considered to be optimal immunogens, as they mimic the original virus infection and activate
all branches of the acquired immune response to target virtually all proteins encoded by the viral
genome [32]. By contrast, a subunit vaccine is able to induce acquired immunity to only one or a
few viral proteins contained in the vaccine, and it often depends on the quality of added adjuvants
to compensate for the strong B and T cell responses induced by active viral replication. However,
the status of most viral glycoproteins, including VZV gE, as genuine membra e-spanning proteins,
makes them unique targets for two important antiviral effects of the B cell response. First, as they
protrude from the viral envelope, they function as targets for neutralizing antibodies and, second,
owing to their position as constituents in the virus-infected cell, they serve as targets for antibodies,
participating not only in antibody-dependent cellular cytotoxicity (ADCC) but also in prevention of
viral cell-to-cell spread. However, the present knowledge regarding B cell responses to gE, following
vaccination with any of the two HZ vaccines, is sparse. It has been reported that Zostavax® induces
antibodies, primarily against gE, as determined by clonal expansion of B cells [33], but no such data are
available for the recombinant subunit vaccine, although it elicits a stronger gE-specific Th1 memory
response compared to the live attenuated vaccine [9,10].
Since the immunocompetent individual who has encountered a primary VZV infection is believed
to be protected from disease caused by reinfection, knowledge on the different antibody specificities
generated by primary VZV infection is also of relevance for understanding of the function of a
successful HZ vaccine. Here, we compared the reactivity to VZV gE of naturally occurring antibodies
in sera drawn from patients, with special reference to possible differences in O-linked glycosylation of
the gE species of the subunit and live vaccine formulations, respectively. This strategy was based on the
following considerations: (i) The two most efficient subunit vaccines to enveloped viruses, i.e., VZV gE
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against HZ and HBsAg against HBV infection, are both based on viral glycoproteins containing MLDs
decorated by numerous short O-linked glycans [15,16,24,25]. (ii) Short O-linked glycans, together with
their surrounding oligopeptide environment, constitute immunoreactive epitopes in viral glycoproteins
with MLD [21,34]. (iii) In contrast to N-linked glycans being added by one single enzyme species,
strongly homologous over the entire animal kingdom, the initiation of O-linked glycans is carried
out by twenty different isotypes of GalNAc transferases, differing in target specificity [27,35]. This
results in prominent, species- and tissue-dependent differences in the glycan occupancy patterns
of the potential O-glycosylation sites of one and the same viral glycoprotein MLD. (iv) Shingrix®
is derived from a hamster ovary cell line, whereas Zostavax® is derived from human fibroblasts,
providing potential for considerable differences in the O-glycan occupancy pattern of gE between the
two immunogens [36].
When analyzing the global O-glycosylation pattern, the most prominent difference between
gEHP as determined in the present study and previously published data for gEL is that gEL is
considerably more densely O-glycosylated than gEHP, i.e., a considerably higher number of the
potential O-glycosylation sites are occupied by glycans [16]. This difference was, in particular,
dominant for O-glycan epitope cluster I (GC-I; Figure 2), harboring epitopes reacting with a majority
of sera from VZV-infected patients. The present data, based on analysis of glycosylated and
non-glycosylated peptides representing the area containing the linear B cell epitope (including GC-I),
clearly demonstrated that O-glycosylation interfered with the reactivity of patient sera to epitopes
of this region of VZV gEHP. Translated into the vaccine situation, this would suggest that gEHP
has a greater potential to present the relevant GC-1 epitopes to the immune response than gEL, for
which such epitopes are blocked by additional O-linked glycans. It is possible that different batches
of CHO-K1 cells exhibit different glycosylation status and, therefore, generate differences in site
occupancy regarding O-linked glycans, making an extrapolation of our data uncertain. However, it has
previously been shown that CHO-K1 cells express only a handful of GalNAc transferases [37] and
that externally added GalNAc transferase increases O-glycan site occupancy [38]. This indicates that
CHO-K1 cells are, in fact, defective in O-linked glycan initiation, generating less densely glycosylated
proteins and, therefore, could be suitable for vaccine production.
In sharp contrast to the function above, O-linked glycans may also be engaged in promoting
reactivity of viral glycopeptide epitopes to cognate antibodies from convalescent sera, which has been
investigated in detail for MLD-containing glycoproteins of herpes simplex virus type 1 and 2 and
Epstein–Barr virus (EBV) [22,23,34]. Model studies demonstrated that the innermost GalNAc unit of
an O-glycan-containing peptide epitope constitutes an equally efficient binding determinant to the
binding paratope of the cognate antibody as does any of its surrounding amino acids [21]. Elimination
of the GalNAc unit results in an immunologically inert peptide epitope with no reactivity to patient
sera. This phenomenon is of relevance here for a family of glycopeptide stretches situated in the GC-III
cluster within the MLD region of gEHP, where each of the same short peptide sequences may form
immunologically distinct glycopeptide GalNAc glycoforms, dependent on the exact position of the
GalNAc unit attached to the peptide. The glycopeptide E505–P522 is of particular interest in this
context, since different patient sera reacted to different glycoforms of this glycopeptide (Figure 6).
One interpretation of this phenomenon, which also has been demonstrated for the seroreactivity of
EBV-infected individuals [21], is that even for a short peptide sequence, different patients modify
different glycosylation sites with GalNAc, owing to patient-dependent differences in expression levels
of the 20 human glycosyltransferases in the cells in which the virus replicates.
At present, it is not fully clear as to what extent differences in O-linked glycosylation may account
for the difference in vaccine efficacy between Zostavax® and Shingrix®, but our data provide detailed
information as to how O-linked glycans affect presentation of important B cell epitopes. Firstly,
previously published data demonstrate that production of gEL in fibroblasts results in extensive
O-linked glycosylation, both with respect to the number of glycans and the size of each glycan
compared with the current data for gEHP, produced in CHO cells [16]. The results here presented
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clearly demonstrated that O-linked glycans of the GC-I cluster (Figure 2) interfere with the display
of antibody recognition epitopes, targeted by antisera from patient that have recovered from VZV
infection. The lower rate of O-glycan site occupancy of gEHP compared with gEL may therefore
constitute an advantage for Shingrix® to induce B cell responses to VZV gE that mimic the protective
antibody profile induced by an active VZV infection. Secondly, data accumulated here for VZV
infection, and elsewhere for EBV infection, indicate that different individuals that have responded to a
virus infection induce antibodies to different glycopeptide glycoforms of a defined peptide stretch,
even as short as 5–8 amino acids long [21,34]. Our data demonstrated that most of these different
glycoforms of the various glycopeptides that reacted to patient sera were in fact represented among the
gEHP glycoprotein species produced in CHO cells. Thirdly, we observed that within the total fraction
of gEHP, only a subpopulation of the peptides carried O-linked glycans at defined positions. Also,
it appeared that certain positions within gEHP carried an O-linked glycan at higher frequency than
other positions, indicating that the protein is also heterogeneously decorated with O-linked glycans
when produced in CHO cells. This suggests that Shingrix® based on gEHP is versatile as an immunogen,
with the capacity to induce antibodies to a wide variety of the variable glycopeptide epitopes that may
be expressed in an idiotypic manner among patients. The finding of minute amounts of nonhuman
sialic acid, NeuGc, in gEHP suggests that this construct may have additional adjuvant qualities in
comparison to gEL. However, this phenomenon needs further confirmation in a separate study.
The difference in O-glycosylation patterns between Zostavax® and Shingrix® may well be
explained by important differences in the principles for their respective productions. Thus, Zostavax®
is produced in a diploid human cell line, characterized by a dense O-linked glycosylation [39]
and, moreover, the vaccine consists of mature virus particles, two factors favoring a high degree
of glycosylation site occupancy with mature O-linked glycans. By contrast, Shingrix® constitutes
molecular gE, obtained from a tumor cell line characterized by moderately sized glycans [36]. Moreover,
our data suggest that gE production in CHO cells is leaky, permitting different gE glycosylation
intermediates into the vaccine preparation. Although the initial step in O-linked glycosylation, i.e.,
the addition of the innermost GalNAc units to the gEHP MLD could be carried out in a seed and
spread manner (i.e., some O-glycosylation sites can only accept GalNAc provided that adjacent
O-glycosylation sites are already occupied; see [20]), the elongation of the glycan chain seems less well
controlled in CHO cells compared to diploid human fibroblasts. This would enable the biosynthesis of
multiple gEHP intermediate glycoforms in the producer cell, which may explain the unique capability
to express most of the many variable glycopeptide epitopes targeted by the panel of positive VZV sera
analyzed here.
Evidently, the data of the present study focusing on one biochemical trait cannot explain,
alone, the complex biology behind the difference vaccine efficacy between Zostavax® and Shingrix®.
However, the results here demonstrate important differences between the two regarding the major
posttranslational modifications of an immunologically active component of both vaccines. Moreover,
all these differences are associated with improved presentation of potential neutralization epitopes to
B cell immunity effectors, and may therefore account, at least partly, for the higher reported efficacy
of Shingrix® compared with Zostavax®, a notion that may be of a broader vaccinology relevance.
Thus, in addition to herpesviruses, viral glycoproteins equipped with MLDs are major pathogenetic
factors for several severe viral infections, including those caused by Ebola virus, Zika virus, tick-borne
encephalitis virus, and others [40–44]. Efforts to optimize the O-linked glycan patterns are likely to
form a cornerstone in the design of efficient vaccines, also against these viruses.
4. Material and Methods
4.1. Expression of Recombinant gE in CHO Cells
The protocol for producing gEHP in CHO-K1 cells has been previously described [31]. Briefly,
the coding sequence of the extracellular domain from the VZV strain Dumas (amino acids 1–539) was
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amplified by PCR using DNA from VZV-infected green monkey kidney (GMK) cells and inserted into
a pcDNA6/myc-His A vector (Invitrogen, Carlsbad, CA, USA) in frame with a 3′ 6×His-tag, creating a
pcDNA6/VZVgE/His construct. The CKO-K1 subclone of CHO cells was obtained from the American
Tissue Type Collection. The CHO-K1 cells were transfected with the pcDNA6/VZVgE/His construct
complexed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and, thereafter, the positive
clones were selected in medium containing 10 µg/mL Blasticidin-HCl (Invitrogen, Carlsbad, CA,
USA). The clones selected for high expression of the gEHP were expanded and adapted to serum-free
suspension growth. In order to produce significant amounts of gEHP, the selected clones were grown
in a 3 L bioreactor (Applikon Biotechnology, Schiedam, The Netherlands). Cell-free growth medium
was harvested continuously and, in total, 12.5 L gE-containing medium was collected. The collected
bioreactor product was concentrated by centrifugation and thereafter applied to a HiTrap chelating
column (GE Healthcare, Uppsala, Sweden) loaded with Co2+. The bound gE-6×His protein was eluted,
and the identity verified by Western blot using a mouse monoclonal antibody VZV g Esc-56994 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and a goat anti-mouse immunoglobulin antibody coupled
to alkaline phosphatase (Southern Biotech, Birmingham, AL, USA). The protein concentration was
determined using a BCA protein assay kit (Thermo Scientific, Rockford, IL, USA).
4.2. LC–MS/MS Analysis
The gEHP (10 µg) was protease digested with trypsin (sequence grade, Promega) and (3 µg) with
pronase (Streptomyces griseus; Roche Diagnostics) using a modified filter-aided solid phase (FASP)
extraction procedure [45]. For this, 30 kDa MWCO Pall Nanosep (Sigma) was used. Cysteine alkylation
was carried out using dithiothreitol (DTT) and S-methyl methanethiosulfonate (Thermo Scientific).
The digestion buffer, 50 mM TEAB (triethylammonium bicarbonate), was supplemented with 1% SDC
(sodium deoxycholate) which was removed with 10% TFA (trifluoric acid) after digestion. Peptides
was purified according to the protocol using Pierce C18 spin columns (Thermo Scientific) and dissolved
in 15 µL of 0.1% formic acid in 3% acetonitrile.
Glycopeptides were analyzed on an Orbitrap Fusion Tribrid mass spectrometer interfaced to an
Easy-nLC 1000 (Thermo Fisher Scientific). Peptides (2 µL injection volume) were separated using an
analytical column (200 mm × 0.075 mm I.D., alternatively, 350 mm × 0.075 mm I.D.) packed in-house
with 3 µm (20 cm long, MS method 1) or 1.8 µm (35 cm long, MS method 2) Reprosil-Pur C18-AQ
particles (Dr. Maisch, Germany). The following gradient was run at 200 nL/min and 55 ◦C; 3%–50%
B-solvent (acetonitrile in 0.2% formic acid) over 30 min, 50%–80% B over 5 min, with a final hold at
80% B for 10 min. Ions were injected into the mass spectrometer under a spray voltage of 1.6 kV in
positive ion mode. MS scans were performed at 120,000 resolution, m/z range 380–1800, and MS/MS
analysis was performed in a data-dependent mode, with a top speed cycle of 3 s for doubly or multiply
charged (up to z = 7) precursor ions. There were two sets of MS method parameters.
Settings for MS method 1: Firstly, the precursors with the highest charged state and then the most
intense ions in each MS scan over threshold 50,000 were selected for fragmentation (MS2) by high
energy collision-induced dissociation (HCD) at 30%, with detection in the Orbitrap at 30,000 resolution.
When product ions at m/z 204.0867, 138.0545, or 366.1396 were present, then the fragmentation (MS2)
for those precursors were triggered. This second MS2 was performed with electron transfer dissociation
(ETD) at 100 ms with 200 K reagent target and supplemental high energy collision-induced dissociation
(HCD) of 10%, with detection in the Orbitrap at 60,000 resolution, m/z range 120–2000. Precursors were
isolated in the quadrupole with a 2.0 m/z window, and dynamic exclusion within 10 ppm for 20 s was
used for m/z values already selected for fragmentation.
Settings for MS method 2: Sequentially to the MS2 scan HCD at 30% as above, a HCD MS2 scan
at 40% was performed. Precursors were here isolated in the quadrupole with a 2.5 m/z window.
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4.3. LC–MS/MS Data Analysis
The MS/MS raw files were transformed into Mascot generic format (.mgf) using Mascot distiller
(Matrix Science, London, UK) and sequence searches were conducted using an in-house Mascot server.
The search database consisted of the gE sequence (Uniprot ID P09259), and the enzyme was set to trypsin
or to no enzyme for the trypsin- and pronase-cleaved samples, respectively. Methylthio-derivatization of
Cys (45.9877 u) was set as a static modification, and Met oxidation was set as an allowed modification.
For HCD spectral searches, HexNAc (203.0794 u), HexHexNAc (365. 1322 u), NeuAcHexHexNAc
(656.2276 u), and (NeuAc)2HexHexNAc (947.3230 u) were set as allowed modification of Ser, Thr, and
Tyr residues and, additionally, the same masses were set as allowed neutral losses of peptide backbone
fragmented ions containing the arbitrarily chosen glycosylation site. For ETD spectral searches, the
same glycan modifications were used but without any fragmentation loss of the glycans. For pronase
samples, extracted ion chromatograms of diagnostic oxonium ions were prepared, for instance, m/z
138.055 for HexNAc-containing glycopeptides and m/z 290.087 for NeuGc-containing glycopeptides.
Hits were assigned by using the tentatively assigned peptide ion, or the peptide+HexNAc ion for
N-glycopeptides, as input in the Find peptide web service (Expasy, Swiss institute of bioinformatics).
The glycan structure for each glycopeptide was assigned by annotating the glycosidic fragmentation
pattern together with the mass difference between the precursor and MS/MS-generated peptide ions.
4.4. Deglycosylation of gEHP
Neuraminidase (α2-3, α2-6, and α2-8 linked sialic acid residues), PNGaseF (high mannose,
hybrid and complex type N-linked glycans), and O-glycosidase (core 1 and core 3 O-linked glycans)
(all from New England Biolabs, Ipswich, MA, USA) were used to remove glycans from the gEHP.
In brief, 40 µg gEHP was combined with 10× glycobuffer to a volume of 20 µL. Subsequently, either
4 µL neuraminidase (5 × 104 U/mL), 4 µL PNGaseF (5 × 105 U/mL), or a combination of 4 µL
neuraminidase and 4 µL O-glycosidase (4 × 107 U/mL) was added, together with ddH2O, to achieve a
final volume of 40 µL. The samples were subsequently incubated at 37 ◦C for one hour and then placed
on ice before storage at −20 ◦C. To evaluate the glycan removal, the glycosidase-treated gEHP was
incubated with sample buffer and heated at 95 ◦C for 10 min. The samples were loaded on a Novex
NuPAGE Bis-Tris 4%–12% 1 mm gel using MOPS running buffer including NuPAGE antioxidant
prepared according to the manufacturer instructions (Invitrogen, Carlsbad, CA, USA). For protein size
determination, the PageRuler Prestained Protein Ladder (Thermo Scientific, Rockford, IL, USA) was
included in the gel. The gel was subsequently stained with Novex Colloidal Blue stain according to
the instructions from the manufacturer (Invitrogen, Carlsbad, CA, USA).
4.5. Serology Using Deglycosylated gEHP
The different preparations of partially deglycosylated gEHP were diluted to a final concentration
of 1 ng/mL in carbonate buffer pH 9.6, and 100 µL of each diluted preparation was applied to a
96-well Maxisorp-plate. Additionally, untreated gEHP at a concentration of 1 µg/mL was added as a
control. The plate was sealed with an adhesive plastic film and incubated at 4 ◦C, overnight. After
adsorption of the antigens, the plates were washed three times in wash buffer (PBS supplemented
with 0.05% Tween 20). To prevent unspecific binding, the plates were incubated with blocking solution
(PBS with 2% skimmed milk) for 30 min at room temperature. Thereafter, the plates were washed
three times in wash buffer before addition of human sera from VZV-positive individuals, with high
anti-VZV IgG antibody titer (n = 5) and intermediate anti-VZV IgG titer (n = 5) as determined by
ELISA (whole virus or gE antigen) and immunofluorescence of VZV-infected cells. All sera were
obtained from the routine diagnostic laboratory of Clinical Virology, at the Sahlgrenska University
Hospital, Gothenburg, Sweden. The Medical Ethics Committee at University of Gothenburg approved
the study; Dnr: 307-06. The study has been performed in accordance with the ethical standards laid
down the Helsinki agreements and its later amendments. The serum samples were diluted in PBS
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containing 1% skimmed milk and 0.05% Tween 20. The plates were incubated at 37 ◦C for 90 min. After
an additional three washes in wash buffer, 100 µL alkaline phosphatase-conjugated goat anti-human
IgG antibody, diluted 1:1000 in PBS with 1% skimmed milk and 0.05% Tween 20, was added to each
well. The plates were then incubated at 37 ◦C for one hour and thereafter washed three times in wash
buffer. Finally, 200 µL of 1 mg/mL phosphatase substrate (4-nitrophenyl phosphate disodium salt
hexahydrate) (Sigma Aldrich, St. Louis, MO, USA), diluted in diethanolamine (DEA) buffer, was
added to each well, and absorbance was measured after 20 min at 405 nm with background reading at
620 nm using an Emax Precision microplate reader (Molecular Devices, Sunnyvale, CA, USA).
4.6. General Procedure for Synthesis of Peptide Library
Peptides were prepared by Fmoc solid-phase peptide synthesis on a Syro Wave automated
peptide synthesizer (Biotage, Sweden). Syntheses were carried out on TentaGel R Rink Amide
0.19 mmol/g, (Rapp Polymers GmbH, Germany). Amino acids had Fmoc protection of
Nα-amino groups; side chain-protecting groups were tert-butyl (Ser, Thr, Glu, and Asp), 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (Pbf, for Arg), trityl (Trt, for Asn, Gln, and His), and
tert-butyloxycarbonyl (Boc, for Lys); acetonitrile, formic acid, triethylsilane (TES), sodium methoxide
solution (0.5 M), trifluoroacetic acid (TFA), and dichloromethane (DCM) were purchased from
Sigma-Aldrich (Denmark). Common amino acids, 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-
dioxaoctanoic acid (Fmoc-O2Oc-OH), and other reagents for peptide synthesis were supplied by Iris
Biotech (Germany). N-α-Fmoc-O-β-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-galactopyranosyl)-
L-threonine (Fmoc-Thr(β-D-GalNAc (Ac)3)-OH) was supplied by Sussex Research Laboratories Inc.
(Ontario, Canada). Purification was performed by RP-HPLC (Dionex Ultimate 3000 system) with
preparative C4 (Phenomenex, Luna 300Å 5 µm C4 particles, 21.5 × 250 mm and C18 columns FeF
Chemicals, 300Å 5 µm C18 particles, 21.5 × 250 mm) using the following solvent system: water
containing 0.1% TFA (solvent A), and methanol containing 0.1% TFA (solvent B).
Synthesis was carried out on a TentaGel R Rink Amide 0.19 mmol/g using 5 equivalents of
amino acids and 1-hydroxy-7-azabenzotriazole (HOAt), 4.8 equivalents of N-[(1H-benzotriazole-1-yl)
(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HBTU) and
9.8 equivalents N,N-diisopropylethylamine (DIEA). During coupling of Fmoc-Thr(β-D-GalNAc(Ac)3)-OH
only 1.1 equivalent of the amino acid and HOAt, 1 equivalent HBTU, and 1.7 equivalent of DIEA was
used. Double couplings were performed throughout the synthesis with a coupling time of 2 × 10 min
at 75 ◦C with NMP, and washing in between. For the first 20 couplings, deprotection of Nα-Fmoc was
done by addition of piperidine–DMF (2:3) for 3 min, followed by piperidine–DMF (1:4) for 2 × 10 min,
then a washing step with NMP and further piperidine–DMF (1:4) for 10 min. After each coupling and
deprotection, a washing procedure with 3 × NMP, 1 × DCM, and 3 × NMP was performed. From
then on, two extra 10 min deprotection steps with piperidine–DMF (1:4) were performed. The resin
was washed six times with DCM after completion of synthesis.
The peptides were released from the solid support by treatment with trifluoroacetic acid (TFA),
triethylsilane (TES), and H2O (95:2:3) for 2 h. The TFA solutions were concentrated by nitrogen flow,
and the compounds were precipitated with diethyl ether to yield the crude product. The crude peptide
was purified on a C4 column, followed by three subsequent purification steps on a C18 column. Peptide
identification was carried out by electrospray ionization mass spectrometry (ESI–MS) (MSQ Plus Mass
Spectrometer, Thermo). Purity was evaluated by analytical HPLC (Dionex Ultimate 3000 system) on
an analytical C18 column (Phenomenex Gemini NX 110 Å, 5 µm, C18 particles, 4.60 × 50 mm) using a
linear gradient flow of water–methanol containing 0.1% formic acid (5%–100% methanol for 15 min).
4.7. Print of Microarrays
All peptides were diluted 1:20 in print buffer (150 mM sodium phosphate, 0.005% CHAPS{3-
[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, 0.03% NaN3; pH 8.5). Peptides 27–48
were further diluted to 1:60. The peptides were then immobilized on N-hydroxysuccinimide (NHS)
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slides (Schott Nexterion, SlideH) on a 16-well format with 18 × 18 spots, with a Biorobotics Microgrid
II spotter (Genomics Solution) using Stealth 3B microspotting pins (Arrayit) with approximately 6 nL
per spot. Each peptide was deposited in triplicates in 16 identical subarrays. After printing, the slides
were incubated at 70% humidity for 60 min, and the remaining NHS groups were deactivated in
blocking buffer (50 mM ethanolamine in 50 mM borate buffer; pH 8.5) for 2 h, and then rinsed in
Millipore water and spun dry.
4.8. On-Slide Glycosylation of Synthetic Peptides
Blocked slides were fitted with a 2-well superstructure (Fast frame, Schleicher & Schuell
(Whatman)), to form two wells. The wells were filled with 500 µL of glycosylation mixture
(10 µL of 100 mM UDP-GalNAc, 10 µL of either 0.36 mg/mL GalNAc-transferase 2 (GalNAc-T2), or
0.46 mg/mL GalNAc-transferase 3 (GalNAc-T3) 10 mM, and 480 µL HEPES buffer (10 mM containing
0.1 mM CaCl2, 2 mM MnCl2, 0.15 mM NaCl; pH 7.5), placed in a humidification chamber, and
incubated for 2 h at RT. Slides were then washed with 0.1 M acetic acid (2 × 5 min, shaking) and
PLI-P (5 min, shaking). Slides were again washed with PBS, rinsed thoroughly with water, dried by
centrifugation, and were then ready to be immediately used in a subsequent lectin-binding experiment.
Slides were incubated with biotinylated Vicia villosa (VVA) lectin (1:500 dilution in PLI-P buffer (0.5 M
NaCl, 3 mM KCl, 1.5 mM KH2PO4, 6.5 mM Na2HPO4, and 3% bovine serum albumin (BSA); pH = 7.4)
for one hour at room temperature, followed by incubation with streptavidin-AlexaFluor 647 (1:1000
dilution in PLI-P) for one hour. All incubation steps were performed in a humidification chamber
and were separated by three washing steps in phosphate buffer saline (PBS). After a final wash in
PBS, slides were rinsed in water, dried by centrifugation, and scanned. The images were analyzed,
quantified, and scanned as described below.
4.9. Serology Using a Synthetic Peptide Epitope Microarray
Sera either positive (n = 11) for VZV IgG or negative for VZV IgG (n = 11), as determined by
ELISA (whole virus and gE antigen) and immunofluorescence of VZV-infected cells, were diluted (1:5)
in PLI-P buffer (0.5 M NaCl, 3 mM KCl, 1.5 mM KH2PO4, 6.5 mM Na2HPO4, and 3% BSA; pH = 7.4).
All sera were obtained from the routine diagnostic laboratory of Clinical Virology, at the Sahlgrenska
University Hospital, Gothenburg, Sweden. For the secondary staining, goat anti-human IgG-Cy3
construct (10 µg/mL; Sigma-Aldrich) was diluted in PLI-P buffer 1:500. The subarray wells were filled
with 90 µL each of sample solution (primary or secondary alike). All incubation steps were performed
in a humidification chamber at room temperature (overnight for sera incubation and one hour for
secondary staining) and were separated by three wash steps in PBS. After a final wash in PBS, slides
were rinsed in water, dried by centrifugation, and scanned. The images were analyzed and quantified.
The slides were scanned with a microarray scanner (ProScanArray; Perkin Elmer) equipped with
three lasers for excitation at 488, 543, or 633 nm. The scanned images were analyzed with Scanarray
Express software. For Cy3 fluorescence, 543 nm (excitation) and 570 nm (emission) were used. Spots
were identified using automated spot-finding with manual adjustments for occasional irregularities.
The mean value of relative fluorescence intensity was used, and the spot intensities were determined
by subtracting the median pixel intensity of the local background from the average pixel intensity
within the spots. Triplicate spots were averaged. Serum samples with a relative fluorescence value
higher than two standard deviations over the mean of the control group were designated reactive
towards a peptide.
4.10. Statistical Analysis
Average relative fluorescence (RFU) values were compared using one-way ANOVA and Tukeys´s
multiple comparisons test using the GraphPad 6 Prism software (GraphPad Software Inc., San Diego,
CA, USA). A p-value < 0.05 was considered significant.
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5. Conclusions
We defined that the glycosylation profile of VZV gE expressed in CHO-K1 cells, the same cell
type used for production of the subunit vaccine Shingrix, is different compared to gE derived from
human fibroblasts, that are used for production of the live vaccine Zostavax. The O-linked glycan
occupancy is less dense in gE from CHO-K1 cells and this may increase the exposure of the B cell
epitopes compared to the situation in gE from fibroblasts. We also found evidence for both interference
and enhancement of antibody binding, that were dependent on specific O-linked glycans. The results
demonstrate important differences between Shingrix and Zostavax and could be part of an explanation
for the observed superior efficacy of the subunit vaccine.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/4/
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